{"id":"W4411281412","doi":"10.1080/14796694.2025.2511470","title":"LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Institute of Cancer Research","funders":"Genentech; Astellas Pharma; Eisai; EMD Serono; Rakuten Medical; Daiichi Sankyo Europe; Sanofi; Exelixis; Amgen; Relay Therapeutics; Gilead Sciences; Pfizer; Break Through Cancer; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Agios Pharmaceuticals","keywords":"Medicine; Pembrolizumab; Oncology; Internal medicine; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001508415,0.0002870591,0.001736938,0.0005379044,0.00005524331,0.00001332985,0.0001428834,0.0002460693,0.0007028147],"category_scores_gemma":[0.0002332341,0.0002011276,0.0002599463,0.0006342083,0.0001842425,0.00006226351,0.00003760678,0.0003340002,0.000002963017],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003104381,"about_ca_system_score_gemma":0.001070531,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001380779,"about_ca_topic_score_gemma":0.0005285729,"domain_scores_codex":[0.9972036,0.0005336538,0.001308233,0.0004195468,0.0001916567,0.0003433001],"domain_scores_gemma":[0.9983431,0.0006644195,0.0004513621,0.0003598979,0.00009495906,0.00008627809],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.2223631,0.002517056,0.00029257,0.0004900023,0.001065822,0.000214483,0.002194203,6.760565e-7,0.05838554,0.0007106742,0.01077268,0.7009932],"study_design_scores_gemma":[0.2073521,0.0101739,0.003689136,0.000625528,0.000731695,0.0002736267,0.002756024,0.0001207335,0.01723218,0.0003820823,0.7563028,0.0003601583],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9517723,0.02814639,0.0002043353,0.01131542,0.001921276,0.002046644,0.00007957502,0.00005643818,0.004457651],"genre_scores_gemma":[0.9713837,0.01727257,0.002336334,0.004508378,0.0007401158,0.0003367219,0.00008786706,0.00005336408,0.003280971],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7455302,"threshold_uncertainty_score":0.8201745,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04745932149046059,"score_gpt":0.4257728950944811,"score_spread":0.3783135736040205,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}